MARY E PECQUET GOAD
Veterinary in Andover, MA
License number
Massachusetts 3323
Issued Date
Jun 8, 1987
Expiration Date
Feb 28, 2017
Type
Veterinarian
Address
Address
Andover, MA 01810
Professional information
Compositions And Methods For Minimally-Invasive Systemic Delivery Of Proteins Including Tgf-Beta Superfamily Members
US Patent:
2010020, Aug 12, 2010
Filed:
Feb 12, 2010
Appl. No.:
12/705367
Inventors:
Mary Elizabeth Pecquet Goad - Andover MA, US
Denis Schrier - Hopkinton MA, US
Allen Richard Pierce - Acton MA, US
Denis Schrier - Hopkinton MA, US
Allen Richard Pierce - Acton MA, US
International Classification:
A61K 38/19, A61P 19/02, A61P 19/04, A61P 1/16, A61P 13/12, A61P 9/10, A61P 25/16, A61P 27/02, A61P 3/10, A61P 3/04, A61P 35/00, A61P 29/00, A61M 25/00
US Classification:
514 12, 604523
Abstract:
The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent.
Peripheral Administration Of Proteins Including Tgf-Beta Superfamily Members For Treatment Of Systemic Disorders And Disease
US Patent:
2010020, Aug 12, 2010
Filed:
Feb 12, 2010
Appl. No.:
12/705259
Inventors:
Mary Elizabeth Pecquet Goad - Andover MA, US
Melissa M. Haskell - Uxbridge MA, US
Denis Schrier - Hopkinton MA, US
Susan A. Wood - Dedham MA, US
Melissa M. Haskell - Uxbridge MA, US
Denis Schrier - Hopkinton MA, US
Susan A. Wood - Dedham MA, US
International Classification:
A61K 38/18, A61P 19/02, A61P 19/08, A61P 19/10, A61P 19/04, A61P 25/16, A61P 13/12, A61P 9/10, A61P 3/04, A61P 3/10, A61P 1/16, A61M 25/00, A61M 5/00, A61B 17/34
US Classification:
514 12, 604523, 604272, 60416401
Abstract:
The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent.
Peripheral Administration Of Proteins Including Tgf-Beta Superfamily Members For Treatment Of Systemic Disorders And Disease
US Patent:
2012025, Oct 11, 2012
Filed:
Apr 11, 2012
Appl. No.:
13/444282
Inventors:
Mary Elizabeth Pecquet Goad - Andover MA, US
Melissa M. Haskell - Uxbridge MA, US
Denis Schrier - Hopkinton MA, US
Susan A. Wood - Dedham MA, US
Melissa M. Haskell - Uxbridge MA, US
Denis Schrier - Hopkinton MA, US
Susan A. Wood - Dedham MA, US
International Classification:
A61K 38/18, C07K 14/475, A61P 19/08, A61P 19/02, A61P 35/00, A61P 19/04, A61P 1/16, A61P 25/16, A61P 9/10, C07K 14/51, A61P 19/10
US Classification:
514 88, 530399
Abstract:
The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent.